Le Lézard
Classified in: Health, Science and technology
Subject: AWD

ModuleMD Secures Fourth Consecutive Win as G2 High Performers


GRAND BLANC, Mich., May 9, 2024 /PRNewswire/ -- ModuleMD, a leading provider of innovative EHR, Practice Management Software and Revenue Cycle Management (RCM) solutions, proudly announces its fourth consecutive recognition in the G2 High Performers Grid in the EHR software category. The G2 Winter 2024 Grid Report further establishes ModuleMD's reputation as a steadfast and visionary ally for healthcare professionals around the world.

ModuleMD Secures Fourth Consecutive Win as G2 High Performers

As the largest and most trusted software marketplace, G2 guides over 90 million users annually?including employees at all Fortune 500 companies?in making informed software decisions based on genuine peer reviews. With an impressive 94% of reviews on G2 marked as a 4 or 5-star rating for ModuleMD, the consistent recognition as a G2 High Performers Grid Leader underscores the company's dedication to providing exceptional quality, reliability, and customer satisfaction within the healthcare technology landscape. This acknowledgment not only celebrates ModuleMD's achievements, but also solidifies its reputation as a top choice for healthcare professionals seeking superior Healthcare IT software solutions.

Abhinay Penugonda, CEO of ModuleMD, expressed his gratitude, remarking, "We are thrilled to be recognized as a G2 High Performer for the fourth consecutive time. This accomplishment demonstrates our passion for creating industry-leading solutions and ensuring our customers' success. We appreciate the valuable feedback from our loyal customers, which inspires us to continually strive for excellence."

"I was more than happy to share my thoughts on ModuleMD," says Andrea Force, Practice Manager at Allergy Asthma Centers and a loyal ModuleMD customer. "The [ModuleMD] team has always been there for me, and the product just keeps getting better. I'm a firm believer in giving credit where credit is due, and ModuleMD definitely deserves it. When I have a great experience with a company that I truly believe in, I'm always excited to spread the word."

The company's consistent recognition as a G2 High Performers Grid Leader reflects its unwavering commitment to excellence and customer satisfaction. By actively listening to user feedback and embracing industry trends, such as cutting-edge AI technology, ModuleMD has become a resounding voice in the industry, shaping the future of healthcare technology and is a driving force of innovation.

Discover what ModuleMD clients have shared on YouTube

www.modulemd.com 

For user reviews, visit https://www.g2.com/products/modulemd/reviews

ModuleMD Press Contact:

Cheryl Fernandes
[email protected] 

Miranda Moore
[email protected] 

Infographic - https://mma.prnewswire.com/media/2403577/ModuleMD_Infographic.jpg
Logo - https://mma.prnewswire.com/media/2314317/Module_MD_Logo.jpg

 

SOURCE ModuleMD LLC


These press releases may also interest you

at 04:45
ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Announces International Distribution Agreement for VETIGEL with Covetrus
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
New Research by Tea Advisory Panel Reveals That Three Quarters Of Brits Never Drink Tea Before A Workout Despite It Counting Towards Fluid Intake Recommendations
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S DISEASE CELL THERAPY PROGRAM AT THE 29TH WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS (IAPRD) IN LISBON
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

More news about Health...


News published on and distributed by: